Neurocrine Biosciences (NBIX) Receivables - Net (2016 - 2021)
Historic Receivables - Net for Neurocrine Biosciences (NBIX) over the last 12 years, with Q3 2021 value amounting to $163.8 million.
- Neurocrine Biosciences' Receivables - Net rose 439.77% to $163.8 million in Q3 2021 from the same period last year, while for Sep 2021 it was $163.8 million, marking a year-over-year increase of 439.77%. This contributed to the annual value of $157.1 million for FY2020, which is 2409.16% up from last year.
- Per Neurocrine Biosciences' latest filing, its Receivables - Net stood at $163.8 million for Q3 2021, which was up 439.77% from $158.5 million recorded in Q2 2021.
- In the past 5 years, Neurocrine Biosciences' Receivables - Net registered a high of $163.8 million during Q3 2021, and its lowest value of $6.1 million during Q2 2017.
- Its 5-year average for Receivables - Net is $97.6 million, with a median of $105.3 million in 2019.
- Per our database at Business Quant, Neurocrine Biosciences' Receivables - Net surged by 60210.73% in 2018 and then plummeted by 53.84% in 2021.
- Over the past 5 years, Neurocrine Biosciences' Receivables - Net (Quarter) stood at $31.1 million in 2017, then soared by 84.43% to $57.4 million in 2018, then soared by 120.53% to $126.6 million in 2019, then grew by 24.09% to $157.1 million in 2020, then rose by 4.26% to $163.8 million in 2021.
- Its Receivables - Net was $163.8 million in Q3 2021, compared to $158.5 million in Q2 2021 and $147.8 million in Q1 2021.